Cargando…
New anti-cancer chemicals Ertredin and its derivatives, regulate oxidative phosphorylation and glycolysis and suppress sphere formation in vitro and tumor growth in EGFRvIII-transformed cells
BACKGROUND: EGFRvIII is a mutant form of the epidermal growth factor receptor gene (EGFR) that lacks exons 2–7. The resulting protein does not bind to ligands and is constitutively activated. The expression of EGFRvIII is likely confined to various types of cancer, particularly glioblastomas. Althou...
Autores principales: | Atsumi, Sonoko, Nosaka, Chisato, Adachi, Hayamitsu, Kimura, Tomoyuki, Kobayashi, Yoshihiko, Takada, Hisashi, Watanabe, Takumi, Ohba, Shun-ichi, Inoue, Hiroyuki, Kawada, Manabu, Shibasaki, Masakatsu, Shibuya, Masabumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949881/ https://www.ncbi.nlm.nih.gov/pubmed/27431653 http://dx.doi.org/10.1186/s12885-016-2521-9 |
Ejemplares similares
-
EGFRvIII: the promiscuous mutation
por: Greenall, Sameer A, et al.
Publicado: (2016) -
Development of an EGFRvIII specific recombinant antibody
por: Gupta, Puja, et al.
Publicado: (2010) -
Efficacy of osimertinib against EGFRvIII+ glioblastoma
por: Chagoya, Gustavo, et al.
Publicado: (2020) -
Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII(+)PTEN(−) glioblastoma in vivo
por: Xu, Wen, et al.
Publicado: (2016) -
The natural history of EGFR and EGFRvIII in glioblastoma patients
por: Heimberger, Amy B, et al.
Publicado: (2005)